Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efsubaglutide Alfa 3 mg Q2W vs 1 mg QW in T2DM
NCT06900075Phase 3Not yet recruiting
- Sponsor
- Shanghai Innogen Pharmaceutical Technology Co., Ltd.
- Start
- Jul 2025
- Primary completion
- Jan 2026
- Modality
- Peptides, Fc-Fusion Proteins
01
Overview
Phase 3, randomised, open-label trial of efsubaglutide alfa in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Shanghai Innogen Pharmaceutical Technology Co., Ltd. Primary endpoint: Time in Range. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
efsubaglutide alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06900075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06900075.